Advaxis, Inc.
13
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
46.2%
6 terminated/withdrawn out of 13 trials
53.8%
-32.7% vs industry average
8%
1 trials in Phase 3/4
114%
8 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Role: lead
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Role: lead
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Role: lead
A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
Role: lead
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Role: lead
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
Role: lead
Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer
Role: lead
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
Role: lead
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Role: collaborator
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
Role: collaborator
Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
Role: lead
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+
Role: lead
Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal Cancer
Role: collaborator
All 13 trials loaded